WO1995026983A3 - Treatment or diagnosis of abnormal signal transduction disorders - Google Patents

Treatment or diagnosis of abnormal signal transduction disorders Download PDF

Info

Publication number
WO1995026983A3
WO1995026983A3 PCT/US1995/003945 US9503945W WO9526983A3 WO 1995026983 A3 WO1995026983 A3 WO 1995026983A3 US 9503945 W US9503945 W US 9503945W WO 9526983 A3 WO9526983 A3 WO 9526983A3
Authority
WO
WIPO (PCT)
Prior art keywords
interaction
treatment
disease
diagnosis
condition
Prior art date
Application number
PCT/US1995/003945
Other languages
French (fr)
Other versions
WO1995026983A2 (en
Inventor
Axel Ullrich
Gunter Kostka
Axel Obermeier
Oliver Hobert
Bahija Jallal
Original Assignee
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. filed Critical MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Priority to AU22334/95A priority Critical patent/AU2233495A/en
Publication of WO1995026983A2 publication Critical patent/WO1995026983A2/en
Publication of WO1995026983A3 publication Critical patent/WO1995026983A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

A method for treatment of a disorder in an organism characterized by abnormal cellular signal transduction is described. The disorder may be characterized by an abnormal level of interaction between a signalling component such as SHC and an RTK of the Trk family, or the interaction between particular SH3 and MP domains (such as an interaction between an SH3 domain and a DYN domain). The method includes disrupting or promoting that interaction (or signal) in vivo. The method also involves inhibiting the activity of the complex formed between the individual molecules. A method for diagnosis of such a disease or condition by detecting the level of such interaction as an indication of that disease or condition is also described. Also, a method for screening for an agent useful for treatment of such a disease or condition by assaying potential agents for the ability to disrupt or promote that interaction is described. The invention also features peptides consisting essentially of particular MP, DYN and SH3 domains.
PCT/US1995/003945 1994-03-31 1995-03-30 Treatment or diagnosis of abnormal signal transduction disorders WO1995026983A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU22334/95A AU2233495A (en) 1994-03-31 1995-03-30 Treatment or diagnosis of abnormal signal transduction disorders

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22164294A 1994-03-31 1994-03-31
US08/221,642 1994-03-31
US25169194A 1994-05-31 1994-05-31
US08/251,691 1994-05-31
US29159194A 1994-08-15 1994-08-15
US08/291,591 1994-08-15

Publications (2)

Publication Number Publication Date
WO1995026983A2 WO1995026983A2 (en) 1995-10-12
WO1995026983A3 true WO1995026983A3 (en) 1996-02-08

Family

ID=27396973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/003945 WO1995026983A2 (en) 1994-03-31 1995-03-30 Treatment or diagnosis of abnormal signal transduction disorders

Country Status (2)

Country Link
AU (1) AU2233495A (en)
WO (1) WO1995026983A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5117896A (en) * 1995-03-08 1996-09-23 Hospital for Sick Children Research and Development Limited Partnership, The Zap 70 inhibitors and methods for treatment of zap 70 signal transduction disorders
EP0833941B1 (en) * 1995-04-07 2008-10-22 Cytogen Corporation Polypeptides having a functional domain of interest and methods of identifying and using same
WO2002042457A1 (en) 2000-11-22 2002-05-30 Bristol-Myers Squibb Company Cloning and expression of human slap-2: a novel sh2/sh3 domain-containing human slap homologue having immune cell-specific expression
US7101686B1 (en) 2000-11-22 2006-09-05 Bristol-Myers Squibb Company Polynucleotides encoding human SLAP-2:a novel SH2/SH3 domain-containing human SLAP homologue having immune cell-specific expression
WO2002055707A2 (en) * 2001-01-10 2002-07-18 Rigel Pharmaceuticals Inc Cloning of an inhibitor of antigen-receptor signaling by a retroviral-based functional screen
WO2022251584A1 (en) * 2021-05-28 2022-12-01 St. Jude Children's Research Hospital, Inc. Methods and compositions for transduction of nk cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016179A1 (en) * 1992-02-17 1993-08-19 Howard Florey Institute Of Experimental Physiology And Medicine MAMMALIAN Sos - A REGULATOR/EFFECTOR OF TYROSINE KINASE SIGNALLING

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016179A1 (en) * 1992-02-17 1993-08-19 Howard Florey Institute Of Experimental Physiology And Medicine MAMMALIAN Sos - A REGULATOR/EFFECTOR OF TYROSINE KINASE SIGNALLING

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
EGAN, S.E. ET AL.: "Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation", NATURE, vol. 363, pages 45 - 51 *
GOUT, I. ET AL.: "The GTPase dynamin binds to and is activated by a subset of SH3 domains", CELL, vol. 75, pages 25 - 36 *
HERSKOVITS, J. S. ET AL.: "Effects of mutant rat dynamin on endocytosis", J. CELL. BIOL., vol. 122, no. 3, pages 565 - 578 *
MARGOLIS, B. ET AL.: "Tyrosine phosphorylation of vav proto-oncogene product ...", NATURE, vol. 356, pages 71 - 74 *
OBAR, R.A. ET AL.: "Molecular cloning of the microtubule-associated mechanochemical enzyme Dynamin ...", NATURE, vol. 347, pages 256 - 261 *
OBERMEIER, A. ET AL.: "Identification of Trk binding sites for SHC ...", J. BIOL. CHEM., vol. 268, no. 31, pages 22963 - 22966 *
PAWSON, T. ET AL.: "Proteins with SH2 and SH3 domains couple receptor tyrosine kinases to intracellular signalling pathways", PHIL. TRANS. R. SOC. LOND. B, vol. 340, pages 279 - 285 *
REN, R. ET AL.: "Identification of a ten-amino acid proline rich SH3 binding site", SCIENCE, vol. 259, pages 1157 - 1161 *
SCHLESSINGER, J.: "SH2/SH3 signaling proteins", CURR. OPIN. GEN. DEV., vol. 4, pages 25 - 30 *
SIOMI, H. ET AL.: "The pre-mRNA binding K protein contains a novel evolutionary conserved motif", NUCL. ACIDS RES., vol. 21, no. 5, pages 1193 - 1198 *
TAKIMOTO, M. ET AL.: "Specific binding of heterogeneous ribonucleoprotein particle protein K to human c-myc promoter, in vitro", J. BIOL. CHEM., vol. 268, no. 24, pages 18249 - 18258 *
VAN DER BLIEK, A.M. ET AL.: "Mutations in human Dynamin blocks an intermediate stage in coated vesicle formation", J. CELL BIOL., vol. 122, no. 3, pages 553 - 563 *

Also Published As

Publication number Publication date
AU2233495A (en) 1995-10-23
WO1995026983A2 (en) 1995-10-12

Similar Documents

Publication Publication Date Title
CA2222974A1 (en) Magnetic resonance imaging agents for the detection of physiological agents
WO1996018738A3 (en) PROBIN TYROSINE KINASE (PYK2) ITS cDNA CLONING AND ITS USES
WO1999025389A3 (en) Magnetic resonance imaging agents for the detection of physiological agents
CY1109062T1 (en) METHODS OF DETERMINING AND ANTI-VASCULAR Suspension
DE69432298D1 (en) SYSTEM FOR DIAGNOSTICS AND TREATMENT OF THE PROSTATE AND URINARY WAY
WO2007149985A3 (en) Assessing dementia and dementia-type disorders
ATE230863T1 (en) SYSTEM AND METHOD FOR FACILITATING CLINICAL DECISION MAKING
DE3852275T2 (en) Ultrasound probe for intravascular catheters for the treatment of intravascular closures.
DE69600399T2 (en) Use of a CGRP antagonist for the treatment of skin erythema of neurogenic origin and treatment received
WO2000018899A3 (en) Angiotensin converting enzyme homolog and its use
WO2003013343A3 (en) Method for psychophysiological detection of deception through brain function analysis
WO2000034511A3 (en) Aβ-PEPTIDE SCREENING ASSAY
WO2003015615A3 (en) Treatment of muscular dystrophies and related disorders
PT948604E (en) PRODUCTS AND METHODS RELATED TO PYK2
WO1995026983A3 (en) Treatment or diagnosis of abnormal signal transduction disorders
CA2119345A1 (en) Methods for the In Vivo Measurement of the Concentration of NMR-Detectable Xenobiotic Compounds
WO1997012039A3 (en) Sh2-containing inositol-phosphatase
DE69504949T2 (en) Use of an antagonist of substance P for the treatment of skin redness of neurogenic origin
ATE173620T1 (en) USE OF AN ANTAGONIST OF TNF-ALPHA FOR THE TREATMENT OF SKIN REDNESS OF NEUROGENIC ORIGIN
WO1996040113A3 (en) Phosphatase inhibitors
WO2003070195A3 (en) Biglycan and related therapeutics and methods of use
WO2001036475A3 (en) Biglycan and related therapeutics and methods of use
WO1999063116A3 (en) Use of prothymosin in the diagnosis and treatment of endometriosis
WO2001038581A3 (en) Vigilance nucleic acids and related diagnostic, screening and therapeutic methods
Whalley et al. The effect of kininase II inhibitors on the response of feline cerebral arteries to bradykinin and angiotensin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA US US US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA